Rapid Lung NGS Means Clinicians and Patients Don’t Have to Wait

The hope

Targeted cancer genomic profile-guided cancer therapy is improving patients outcomes, as was shown in the IntegraConnect Study and others. Patients treated based on their genomic profile have 22% higher probability of survival two years from diagnosis1.

 

As the number of biomarkers associated with targeted treatments keeps increasing, there is more hope for cancer patients.

Odds of patient survival (OS) with and without a genomic profile available for a treatment decision.

The gaps

But there are still gaps in the process of providing oncologists with the genomic profile data in time. These gaps are hindering patients access to the treatments they could potentially benefit from2.

The solution

Based on the published data and experience of many leading cancer centers, there is an emerging solution for lung and other cancers: rapid next-generation sequencing (NGS).

 

Benefits of Rapid NGS

  • In house, close to the patients, and fast, so you get the complete potentially actionable biomarker results to guide the first line therapy
  • Tissue saving, so even small biopsies or cytological specimens can be analysed, and number of potential re-biopsies is kept to minimum

Prof. Bence Sipos, MD

BAG for Pathology and Molecular Pathology

Stuttgart, Germany

"By selecting the appropriate methods, optimising sample handling, ensuring rapid and reliable results, and collaborating effectively with clinical teams, pathologists can significantly contribute to the success of personalised cancer treatment. Using rapid NGS, we analyse both tissue and liquid biopsy samples, achieving a TAT of up to 3 days in 82% of cases and a failure rate of <1%."3

Addressing tissue sample input challenges

Some tumor samples, such as fine needle aspirates or other cytology samples, are very small. Therefore, it is crucial that NGS technology requires as small a sample input as possible.

  • Some NGS methods, such as those based on hybrid capture technology, require a high sample input
  • Amplicon-based rapid NGS can deliver results from much smaller amounts of material, as shown in the figure; this may be associated with a direct impact on patient outcomes

Rapid NGS is enabling clinicians and reducing biomarker testing costs

In this recorded webinar, learn how the Massachusetts General Hospital (MGH) Center for Integrated Diagnostics (CID) has consolidated a legacy single-gene testing system into one workflow based on fast and automated NGS to produce a rapid lung molecular testing program.

 

View this webinar to:

  • Learn from the experiences of a leading cancer center in consolidation of NSCLC biomarker testing into a Rapid Lung NGS program
  • Understand the positive implications for oncologists and patients with cancer from the oncologist point of view
  • Understand how the new consolidated workflow saves time and resources

Lauren Ritterhouse, MD, PhD

Associate Director

Massachusetts General Hospital

Ibiayi Dagogo-Jack, MD

Thoracic Oncologist

Massachusetts General Hospital

Community-based Rapid NGS offers considerable advantages in clinical cancer care

In this free on‑demand webinar, Dr. Brandon Sheffield of Canada‑based William Osler Health System shares the organization's experience with implementing NGS in routine oncology biomarker testing.

 

In their pilot study, 578 solid tumor samples underwent genomic profiling. All testing was performed by one group of technologists within the same division of the laboratory, achieving a median turn‑around time (TAT) of three business days.4

Dr. Brandon Sheffield, MD

Medical Director, Advanced Diagnostics Physician Lead of Research Department of Laboratory Medicine

William Osler Health System

The benefits of keeping molecular testing in-house as viewed by experts from around the globe

Democratization of NGS is the key to accelerating cancer care. 

 

"Significantly shorter time to results enables faster and optimal treatment decisions."

"Small sample requirement provides biopsy stewardship, tissue saving."

"It improves care coordination between multidisciplinary teams, leading to true personalized medicine."

"Allows for the development of local expertise in biomarker testing to support the future of precision medicine."

Ready to speak with a Thermo Fisher representative?

We will be happy to answer your questions and provide a demo of our NGS solutions.

Subscribe here to stay abreast of the latest news about NGS in precision oncology.

References

1. Aggarwal C et al. JCO Precis Oncol 2023 

2. Sadik et al. (2022) Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer. JCO Precis Oncol. 6:e2200246.

3. Maximising the Synergy of Tumour Tissue and Liquid Biopsy Testing in Oncology Clinical Practice; EMJ Oncology 12.1 2024

4. Sheffield BS et al. Current Oncology (2022) CAP Today Webinar: Community-based rapid NGS offers considerable advantages in clinical cancer care